通过四维心声回声学研究,探索血管氨酸转化酶 (ACE) 基因多态化对高血压中早期扩张功能的影响
Xinyu Cheng1, Zhiyi Zong2, Xiaofei Mei1
1Department of Cardiology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, 215000, China.
BMC cardiovascular disorders
|February 12, 2025
概括
血管氨酸转化酶 (ACE) D等位基因与高血压患者早期的舒张功能障碍有关. ACE基因测试可以改善这种情况的预测.
科学领域:
- 心脏病学 心脏病学
- 遗传学 遗传学 是一个
- 高血压研究 高血压研究
背景情况:
- 高血压是心血管疾病的主要危险因素,包括腹功能障碍.
- 早期检测和预测腹功能障碍对于管理高血压患者至关重要.
- 血管氨酸转化酶 (ACE) 基因多态性在与高血压相关的透缩功能障碍中的作用需要进一步调查.
研究的目的:
- 在高血压患者中调查ACE基因多态和早期腹功能障碍之间的关联.
- 通过四维心声谱来评估ACE基因变异对透静功能障碍的预测价值.
- 评估ACE基因多态性在这个患者队列中的预后影响.
主要方法:
- 选择了274名高血压患者的队列,并使用PCR-RFLP分析了他们的DNA,以寻找ACE基因多态.
- 用四维回声心脏图来评估透缩功能,测量诸如E/e'比率,左心房体积和三回速度等参数.
- 使用统计分析,包括逻辑回归和ROC曲线,以确定ACE等位基因对透缩功能障碍的关联和预测值.
主要成果:
- 与非D等位基组相比,具有ACE-D等位基因的患者表现出显著减弱的透析功能.
- 在ACE-D等位基组 (62.6%) 与非D等位基组 (27.9%) 中,早期扩张性功能障碍的患病率明显高.
- 后勤回归证实,ACE-D等位基因是高血压中早期扩张功能障碍的独立风险因素 (OR=3.83),ROC分析显示了预测值 (AUC=0.667).
结论:
- 在患有高血压的患者中,ACE-D等位基因与早期的扩张性功能障碍有显著的关联.
- 结合心声学评估的ACE基因多态性分析,可以提高对高血压个体的扩张功能障碍的预测.
- 这些发现表明,与ACE基因变异相关的高血压中患有腹功能障碍的遗传倾向.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
460
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
460
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
573
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
573